Manufacturer of drug substance



Similar documents
An Industry Perspective

November The Impact of Biosimilar Competition

PRODUCT INN REFERENCE AUTHORIZATION Omnitrope

BUY. Biosimilar play at attractive valuation BIOCON. Target Price: Rs 640. Key drivers(r&d value (Rs/sh) biosimilar pipeline)

WHITE PAPER AN OUTLOOK ON US BIOSIMILAR COMPETITION

Lessons for the United States: Biosimilar Market Development Worldwide

Biological. Medicines. A Focus on Biosimilar. Medicines

3rd DVFA Life Science Conference 08 June Biosimilars. BIOCEUTICALS Arzneimittel AG. Epoetin zeta A case study

A Comparison of US and EU Biosimilars Regimes

No consensus concerning

GROWTH HORMONE THERAPY

Clinical trial research agreement Agreed schedule 4 or 7 clause amendments

Biologics: Specific Drug Safety Challenges. Violetta B. Kyburz

Commercial Insight Osteoarthritis and Rheumatoid Arthritis

Rx-360 An International Pharmaceutical Supply Chain Consortium

Ted Quiroz Director, Global Clinical Supply Chain Amgen Inc.

CHEM-E4140 Selectivity 12. Pharma Business

Biosimilar By Name and Biosimilar By Nature

Generic Biological Treatments and the Associated Cost Savings

Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus)

ehealthinsight Series: Online Patient Recruitment Strategies

Letter to Shareholders

A World of Biomanufacturing: Shortages or Global Glut?

DPC AGGIORNATO AL 25/04/2011 PER SPECIALITA'

Outcomes of Monitoring Committee Reviews. Medicines Australia Code of Conduct

Annual Press Conference Business Year 2011

Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity

PlantForm Corporation

PATIENT APPLICATION FORM INSTRUCTIONS

Growth Hormone Deficiency

Challenges and Opportunities of Monoclonal Antibody Manufacturing in China

Biosimilars: Commercial Perspective

Key Findings. Use this report to... The Autoimmune Market Outlook to 2013

The Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts to 2011

6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality

Stakeholder Perspectives: Mild Cognitive Impairment and Dementia

Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies

Pharma working capital performance highly variable

Pharmaceutical industry

Multiple Sclerosis Treatments: World Market Outlook to 2011

Biopharmaceutical Raw Materials throughout the Product Lifecycle

Commercial Perspectives: Multiple Sclerosis

Biologics and biosimilars. An overview

HISTORY OF DEVELOPMENT CURRENT INDICATORS DEVELOPMENT PROSPECTS

EU Clinical Trials Register

Multiple Sclerosis Therapeutics to Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth

Stakeholder Insight: Insulin Use in Type 2 Diabetes

Stakeholder Insight: Rheumatoid Arthritis Biologics battle up the treatment algorithm

Palliative Coverage Drug Benefit Supplement

PATIENT ASSISTANCE PROGRAMS

Metastatic Breast Cancer - Pipeline Review, Q1 2011

PHARMACEUTICAL INDUSTRY PROFILE

e-labeling : innovation for patient or regulation nightmare Pharmapack Feb, 11 th, 2015

WORLD PREVIEW 2014, OUTLOOK TO 2020

Company Presentation June 2011 Biotest AG 0

Global Non-Small Cell Lung Cancer Therapeutics Market

Commercial Insight: Disease Modification in Rheumatoid Arthritis - Market awaits game changing therapies and strategies

Briefing Paper on Biological and Biosimilar Medicines

Uses of 2D gel electrophoresis in recombinant protein production. Kendrick Laboratories, Inc

Patient Assistance PROGRAM PRIMER

Total Compensation Measurement. Global TCM Participants. Turkey

Immune-response and adverse reactions: PRCA case example. Nicole Casadevall

Meet Novartis Management

Brochure More information from

Mid-Year Report 2015

KEEPING CLINICAL TRIALS IN AUSTRALIA

(SAMPLE COPY, NOT FOR RESALE)

Pharma working capital leaves room for improvement

Patient Satisfaction and Therapeutic Adherence Considerations of rhgh Dosing Devices

In the largest and perhaps the most ambitious collaborative

REFERENCE CODE GDHC503DFR PUBLICAT ION DATE DECEMBER 2014 METHOTREXATE (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023

The power of creativity Pharmaceutical Branding 2012

Paul K. Wotton, Ph.D President and Chief Executive Officer May 2012 AMEX: AIS

Pharmaceutical Marketing Disclosures

Pipeline Insight: Schizophrenia Asenapine; A future market leader?

M&A und Allianzen in Life Science Aktuelle Entwicklungen und Trends

Source: BIO, Factset, NASDAQ

Triskel: a strategic consulting firm for biopharmaceutical companies

MRC Technology Centre for Therapeutics Discovery

Current Regulatory thinking Around Biosimilars A Regulator s Perspective

Accelerating Drug & Clinical Trial Approvals in China & East Asia

Ahighlight of the Pharma 50 ranking

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal

General toxicity study designs

December 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES

Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants

BIOSIMILARS A COMPLETE DEVELOPMENT PLATFORM

Introduction to Drug Naming. Angela G. Long, M.S. Senior Vice President, Global Alliances and Organizational Affairs

Transcription:

Original s and Biosimilars (marketing authorizations in the EU) Date: January 2016 1) Somatropin s ORIGINAL PRODUCTS: Authorization Genentech Genotropin Somatropin Pharmacia/ Pfizer E. coli Humatrope Somatropin Lilly Lilly E. coli Norditropin Somatropin Novo Nordisk Novo Nordisk E. coli Nutropinaq Somatropin Ipsen Genentech E. coli Somatropin Biopartners Somatropin BioPartners LG Life Sciences Saccharomyces cerevisiae Saizen Somatropin Merck Serono Merck Serono Mouse cells C127 Zomacton Somatropin Ferring Ferring E. coli Omnitrope Somatropin Sandoz Sandoz E. coli Genotropin, Somatropin

2) Filgrastim s ORIGINAL PRODUCTS: Neupogen Filgrastim Amgen Amgen E. coli Granocyte Lenograstim Chugai Pharma Chugai Pharma CHO cells Lonquex Lipegfilgrastim Teva Merckle Biotec E. coli Neulasta Pegfilgrastim Amgen Amgen E. coli Ristempa Pegfilgrastim Amgen Amgen E. coli The two products of Amgen (grey) are one product with two brand names, they are produced in one and the same manufacturing plant, are identical among each other and substitutable among each other. BIOSIMILARS: INN (Name of Filgrastim Filgrastim Hexal Sandoz E. coli Neupogen, Filgrastim Hexal Zarzio Filgrastim Sandoz Sandoz E. coli Neupogen, Filgrastim Ratiograstim Filgrastim ratiopharm SICOR Biotech E. coli Neupogen, Filgrastim Tevagrastim Filgrastim Teva SICOR Biotech E. coli Neupogen, Filgrastim Nivestim Filgrastim Hospira Hospira E. coli Neupogen, Filgrastim Grastofil Filgrastim Apotex Intas Pharmaceuticals E. coli Neupogen, Filgrastim Accofil Filgrastim Apotex Intas Pharmaceutical E. coli Neupogen, Filgrastim The products of Hexal and Sandoz are one biosimlar with two brand names (red); the products of Ratiopharm and Teva with three brand names (blue) are one biosimilar as this is the case for the products of Intas Pharmaceuticals (orange). Biosimilars with several brand names are produced in one and the same manufacturing plant of the generic producer, are therefore identical among each other and substitutable among each other. Seite 2/7

3) Epoetin s ORIGINAL PRODUCTS: Aranesp Darbepoetin alfa Amgen Amgen CHO cells Erypo Epoetin alfa Janssen-Cilag Johnson & CHO cells Johnson Neorecormon Epoetin beta Roche Roche CHO cells Mircera Methoxy-Poly- Roche Roche CHO cells ethylen-glycol- Epoetin beta Biopoin Epoetin theta Teva Merckle Biotec CHO cells Eporatio Epoetin theta Ratiopharm Merckle Biotec CHO cells The products of Teva and ratiopharm (orange) are one product with two brand names, they are produced in one and the same manufacturing plant, are identical among each other and substitutable among each other. BIOSIMILARS: Abseamed Epoetin alfa medice Lek; Rentschler CHO cells Erypo, Epoetin alfa Epoetin alfa Epoetin alfa Hexal Lek; Rentschler CHO cells Erypo, Epoetin alfa Hexal Binocrit Epoetin alfa Sandoz Lek; Rentschler CHO cells Erypo, Epoetin alfa Retacrit Epoetin zeta Hospira Norbitec CHO cells Erypo, Epoetin alfa Silapo Epoetin zeta Stada Norbitec CHO cells Erypo, Epoetin alfa The products of medice, Hexal and Sandoz are one biosimilar with three brand names (red); die products of Hospira and Stada are one biosimilar with two brand names (blue). Biosimilars with several brand names are produced in one and the same manufacturing plant of the generic producer, are therefore identically among each other and substitutable among each other. Seite 3/7

4) Follitropin alfa s ORIGINAL PRODUCT: of drug Gonal-f Follitropin alfa Merck Serono Merck Serono CHO cells BIOSIMILARS: Ovaleap Follitropin alfa Teva Merckle Biotec CHO cells Gonal-f, Follitropin alfa Bemfola Follitropin alfa Finox Biotech Polymun Scientific Immunbiologische Forschung CHO cells Gonal-f, Follitropin alfa Seite 4/7

5) Monoclonal Antibodies ORIGINAL PRODUCT: Remicade Infliximab Janssen Biologics of drug Janssen Biologics Mouse cells Inflectra Infliximab Hospira Celltrion Mouse cells Remicade, Infliximab Remsima Infliximab Celltrion Celltrion Mouse cells Remicade, Infliximab The products of Hospira and Celltrion (red) are one product with two brand names, they are produced in one and the same manufacturing plant, are identical among each other and substitutable among each other. Seite 5/7

6) Insulin glargine s ORIGINAL PRODUCT: of drug Lantus Insulin glargine Sanofi-Aventis Sanofi-Aventis E. coli of drug Abasaglar Insulin glargine Eli Lilly Lilly del Caribe, Eli Lilly and Company E. coli Lantus, Insulin glargin Seite 6/7

7) Fusion proteins ORIGINALPRÄPARAT: Enbrel Etanercept Pfizer Boehringer Ingelheim Pharma, Pfizer Ireland Pharmaceuticals CHO cells of drug Benepali Etanercept Samsung Bioepis Biogen Idec CHO cells Enbrel, Etanercept Seite 7/7